Prognostic value of prognostic nutritional index in patients undergoing surgery for gastric cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
220 patients (161 males, 59 females; mean age: 60.
I · Intervention 중재 / 시술
curative surgical resection for gastric cancer between 2014 and 2020 were retrospectively analyzed
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
PNI is an important marker for predicting long-term survival and postoperative complication risk in patients with gastric cancer. The significantly lower PNI values in the SRCC subtype compared to other histological subtypes indicate the necessity of closer monitoring of nutritional status in this patient group.
[BACKGROUND AND AIM] Gastric cancer is among the commonly occurring cancers worldwide and is one of the leading causes of cancer-related deaths.
- p-value p<0.001
- 95% CI 0.599-0.747
- Sensitivity 78.8%
- Specificity 51.9%
APA
Mülküt F, Ofluoğlu CB, et al. (2025). Prognostic value of prognostic nutritional index in patients undergoing surgery for gastric cancer.. Frontiers in surgery, 12, 1618111. https://doi.org/10.3389/fsurg.2025.1618111
MLA
Mülküt F, et al.. "Prognostic value of prognostic nutritional index in patients undergoing surgery for gastric cancer.." Frontiers in surgery, vol. 12, 2025, pp. 1618111.
PMID
40969308 ↗
Abstract 한글 요약
[BACKGROUND AND AIM] Gastric cancer is among the commonly occurring cancers worldwide and is one of the leading causes of cancer-related deaths. Malnutrition is an important factor affecting the course of disease and treatment response in gastric cancer patients this study aimed to investigate the effect of the Prognostic Nutritional Index (PNI) on postoperative complications and long-term survival in gastric cancer patients, and to comparatively examine PNI values among different histological subtypes.
[METHODS] Data from patients who underwent curative surgical resection for gastric cancer between 2014 and 2020 were retrospectively analyzed. PNI values were calculated using the formula: 10 × serum albumin (g/dl) + 0.005 × lymphocyte count (cells/mm). The optimal cut-off value for PNI was determined through ROC analysis. The relationship between PNI values and clinicopathological features, postoperative complications, 5-year overall survival (OS), and histological subtypes was evaluated.
[RESULTS] A total of 220 patients (161 males, 59 females; mean age: 60.63 ± 10.56) were included in the study. The mean PNI value was 47.15 ± 6.07. ROC analysis established an optimal PNI cut-off value of 46.2 (AUC = 0.673, 95% CI: 0.599-0.747, p<0.001; sensitivity 78.8%, specificity 51.9%). Complication rates were significantly higher in the patient group with PNI < 46.2 ( = 0.006). The 5-year OS rate was 30.0%. Patients with low PNI values had significantly shorter survival (log-rank = 0.001). Major complications were more frequent in patients with low PNI ( = 0.006). Patients diagnosed with signet ring cell carcinoma (SRCC) had significantly lower PNI values compared to other adenocarcinoma subtypes ( = 0.001). PNI values were lower in the presence of perineural invasion ( = 0.005) and lymphovascular invasion ( = 0.032). In multivariate analysis, tumor stage (for Stage I = 0.01, Stage II = 0.034, Stage III = 0.002) and PNI value ( = 0.001) were identified as independent prognostic factors affecting 5-year OS. Conclusion: PNI is an important marker for predicting long-term survival and postoperative complication risk in patients with gastric cancer. The significantly lower PNI values in the SRCC subtype compared to other histological subtypes indicate the necessity of closer monitoring of nutritional status in this patient group. Our results suggest that preoperative PNI assessment could be a valuable parameter in planning patient-specific treatment approaches.
[METHODS] Data from patients who underwent curative surgical resection for gastric cancer between 2014 and 2020 were retrospectively analyzed. PNI values were calculated using the formula: 10 × serum albumin (g/dl) + 0.005 × lymphocyte count (cells/mm). The optimal cut-off value for PNI was determined through ROC analysis. The relationship between PNI values and clinicopathological features, postoperative complications, 5-year overall survival (OS), and histological subtypes was evaluated.
[RESULTS] A total of 220 patients (161 males, 59 females; mean age: 60.63 ± 10.56) were included in the study. The mean PNI value was 47.15 ± 6.07. ROC analysis established an optimal PNI cut-off value of 46.2 (AUC = 0.673, 95% CI: 0.599-0.747, p<0.001; sensitivity 78.8%, specificity 51.9%). Complication rates were significantly higher in the patient group with PNI < 46.2 ( = 0.006). The 5-year OS rate was 30.0%. Patients with low PNI values had significantly shorter survival (log-rank = 0.001). Major complications were more frequent in patients with low PNI ( = 0.006). Patients diagnosed with signet ring cell carcinoma (SRCC) had significantly lower PNI values compared to other adenocarcinoma subtypes ( = 0.001). PNI values were lower in the presence of perineural invasion ( = 0.005) and lymphovascular invasion ( = 0.032). In multivariate analysis, tumor stage (for Stage I = 0.01, Stage II = 0.034, Stage III = 0.002) and PNI value ( = 0.001) were identified as independent prognostic factors affecting 5-year OS. Conclusion: PNI is an important marker for predicting long-term survival and postoperative complication risk in patients with gastric cancer. The significantly lower PNI values in the SRCC subtype compared to other histological subtypes indicate the necessity of closer monitoring of nutritional status in this patient group. Our results suggest that preoperative PNI assessment could be a valuable parameter in planning patient-specific treatment approaches.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.
- Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.
- Correction: Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).